文献速递消化系统肿瘤

七基因特征检测改善MAGIC试验中围手术期化疗胃食管癌患者的预后风险分层

A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
PubMed 文献 · Ann Oncol · 2018-01-01

基于MAGIC试验中202例接受围手术期化疗的胃食管癌患者高质量RNA样本,使用NanoString平台检测定制胃癌基因面板,通过回归分析建立七基因特征将患者分为两个风险组,高、低风险组中位OS分别为10.2个月和80.9个月(HR 5.1,P<0.0001),并在独立验证队列中确认。

要点

  • 七基因特征将围手术期化疗胃食管癌患者分为两个OS显著不同的风险组(HR 5.1,P<0.0001)。
  • 高风险组中位OS为10.2个月,低风险组为80.9个月。
  • 风险分组在仅手术患者(n=118)中无预后价值(log rank P=0.2)。

核心结论

  • 基因风险分组可独立预测接受新辅助化疗的胃食管癌患者预后。
  • 该特征及检测可能有助于在未来围手术期化疗临床试验中对术后化疗进行风险分层。

研究设计与样本

  • MAGIC试验中202例高质量RNA样本,接受围手术期化疗,使用NanoString平台检测定制胃癌基因面板。
  • 通过惩罚性和标准Cox回归识别与总生存相关的基因,生成风险评分并开发NanoString生物标志物检测以分层。
  • 独立数据集作为验证队列。

主要发现

  • 回归和聚类分析定义七基因特征和两个OS不同的风险组(HR 5.1;P<0.0001)。
  • 高风险组中位OS为10.2个月(95%CI 6.5至13.2个月),低风险组为80.9个月(95%CI 43.0个月至不可评估)。
  • 多因素分析显示风险分组对淋巴结转移具有独立预后价值(淋巴结阳性组HR 3.6,P=0.02;高风险组HR 3.6,P=0.0002)。
  • 在仅手术患者中无预后价值(n=118;log rank P=0.2)。
  • 验证队列独立确认了这些发现。

关键数值与推荐

  • 七基因特征风险分组与OS相关:HR 5.1;P<0.0001。
  • 高风险组中位OS 10.2个月(95%CI 6.5至13.2个月),低风险组80.9个月(95%CI 43.0至不可评估)。
  • 多因素分析:淋巴结阳性组HR 3.6,P=0.02;高风险组HR 3.6,P=0.0002。
  • 仅手术患者n=118,log rank P=0.2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph node groups there is still heterogeneity with risk of relapse. We hypothesized that gene profiles from neoadjuvant chemotherapy treated resection specimens from gastroesophageal cancer patients can be used to define prognostic risk groups to identify patients at risk for relapse. PATIENTS AND METHODS: The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial (n = 202 with high quality RNA) samples treated with perioperative chemotherapy were profiled for a custom gastric cancer gene panel using the NanoString platform. Genes associated with overall survival (OS) were identified using penalized and standard Cox regression, followed by generation of risk scores and development of a NanoString biomarker assay to stratify patients into risk groups associated with OS. An independent dataset served as a validation cohort. RESULTS: Regression and clustering analysis of MAGIC patients defined a seven-Gene Signature and two risk groups with different OS [hazard ratio (HR) 5.1; P < 0.0001]. The median OS of high- and low-risk groups were 10.2 [95% confidence interval (CI) of 6.5 and 13.2 months] and 80.9 months (CI: 43.0 months and not assessable), respectively. Risk groups were independently prognostic of lymph node metastasis by multivariate analysis (HR 3.6 in node positive group, P = 0.02; HR 3.6 in high-risk group, P = 0.0002), and not prognostic in surgery only patients (n = 118; log rank P = 0.2). A validation cohort independently confirmed these findings. CONCLUSIONS: These results suggest that gene-based risk groups can independently predict prognosis in gastroesophageal cancer patients treated with neoadjuvant chemotherapy. This signature and associated assay may help risk stratify these patients for post-surgery chemotherapy in future perioperative chemotherapy-based clinical trials.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Smyth EC, Nyamundanda G, Cunningham D, et al. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Ann Oncol. 2018. PMID: 30481267. doi:10.1093/annonc/mdy407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。